V ascular endothelium regulates vascular tone by releasing endothelium-derived relaxing and contracting factors, including nitric oxide (NO), prostacyclin, endotheliumderived hyperpolarizing factor (EDHF), endothelin, and prostaglandin F 2α , all of which regulate vascular homeostasis through multiple mechanisms. When compared with NO 1 and prostacyclin, 2 relatively little is known about the biochemical, physiological, and pharmacological aspects of endothelium-dependent hyperpolarization (EDH). However, EDHF is considered as one of the important endothelium-derived relaxing factors, especially in resistance arteries. 3, 4 During the past 25 years, experiments were performed to clarify the nature of EDHF, identifying several candidates, including K ion, arachidonic acid metabolites, electric gap communications, C-type natriuretic peptide, endogenous cannabinoid, ecto-5′-nucleotidase, and hydrogen sulfide. 5 It is now widely accepted that multiple EDHFs may exist depending on blood vessels and species studied. [6] [7] [8] We and others have previously identified that endothelium-derived H 2 O 2 is one of the major EDHFs in mouse mesenteric arteries, 9,10 porcine coronary arteries, 11 and human coronary and mesenteric arteries. [12] [13] [14] [15] Impaired EDH-type responses have been reported under various pathological conditions, including hypertension, atherosclerosis, hypercholesterolemia, heart failure, ischemia/ reperfusion, and diabetes mellitus, 5,16 indicating the important roles of EDH in the maintenance of cardiovascular homeostasis. Furthermore, we have recently demonstrated that endothelium-derived H 2 O 2 also plays an important role in endothelial metabolic regulation in mice. 17 Vascular endothelial dysfunction plays a critical role in the pathogenesis of metabolic syndrome, such as obesity, diabetes mellitus, and hypertension, all of which cause cardiovascular
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complications, including myocardial infarction, stroke, and heart and renal failure. 18 Recently, the role of AMP-activated protein kinase (AMPK) has attracted much attention as an important regulator of metabolic functions. 19 AMPK is ubiquitously conserved from yeast to humans, and it is multisubstrate serine/threonine protein kinase involved in the regulation of cellular and whole organism energy homeostasis and metabolism. 20, 21 AMPK consists of heterotrimeric complex with a catalytic subunit α and 2 regulatory subunits β and γ, 20 each having ≥2 isoforms (α 1 , α 2 , β 1 , β 2 , γ 1 , γ 2 , and γ 3 ) that are differentially expressed in various tissues and subcellular locations. 22 In the vascular endothelium, both α subunits of AMPK (α 1 and α 2 ) are expressed although AMPKα 1 is expressed to a greater extent than AMPKα 2 . 22 Previous studies have demonstrated that the predominant isoform expressed in vascular endothelial cells is α 1 . 23, 24 However, because most studies were performed using systemic knockout or transgenic mice to examine the role of AMPK, the specific role of endothelial AMPK (eAMPK) on endothelium-dependent responses remains to be examined. 25 Endothelium-dependent vasodilatation is a vital mechanism of blood flow regulation in response to increased metabolic demand. As a metabolic sensor, eAMPK plays an important role in metabolic regulation of blood flow, 24, 26 which is also regulated by endothelial NO synthase (eNOS) 27, 28 through AMPK activation. 29, 30 However, the role of eAMPK in EDH remains to be elucidated. Thus, in the present study, we examined whether eAMPK is involved in EDH and if so, whether it plays a role in blood pressure regulation in mice in vivo.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Characteristics of Endothelial-Specific AMPK-KO Mice
AMPK is ubiquitously detectable in all cells of organism. To examine the role of eAMPK selectively, we newly generated eAM f/f mice, respectively, because genotype is different in each group. All mice were genotyped by polymerase chain reaction on tail clip samples ( Figure IA in the online-only Data Supplement). We also confirmed endotheliumselective knockdown of AMPK isoforms in the aorta, mesenteric, and coronary arteries by immunofluorescence staining method as described in our previous study ( Figure 1 ). 17, 31 Characteristics of mice, including body, organ, and fat weights and blood and lipid profiles, are shown in Table I 
Role of eAMPK in Blood Pressure Regulation
To study the role of eAMPK in blood pressure regulation in vivo, we monitored blood pressure of eAMPK-KO and control mice by telemetry in vivo. When compared with controls, mean, systolic, and diastolic arterial pressures were significantly higher in eAMPKα 1 −/− significantly increased in all groups ( Figure III in the onlineonly Data Supplement). Thus, the present results indicate that eAMPKα 1 is the dominant catalytic subunit of AMPK in blood pressure regulation.
eAMPK Regulates EDH Responses
In the organ chamber experiments, we used isolated aorta and mesenteric arteries, which can contract in response to 60 mmol/L of KCl ( Figure V in the online-only Data Supplement). In the aorta, acetylcholine-induced endothelium-dependent relaxations were comparable among all eAMPK-KO and control mice, and the responses were inhibited by Nω-nitrol-arginine (L-NNA; 100 μmol/L, an inhibitor of NOS) and indomethacin (10 μmol/L, an inhibitor of cyclooxygenase; Figure  VI in the online-only Data Supplement). However, in mesenteric arteries of controlα 1 f/f α 2 f/f mice, acetylcholine-induced endothelium-dependent relaxations were resistant to L-NNA and indomethacin but were highly sensitive to the combination of apamin and charybdotoxin in the presence of L-NNA and indomethacin, a consistent finding with EDH-mediated relaxations. 9, 10, 17, 33 In contrast, in mesenteric arteries of eAMPKα 1 −/− α 2 −/− mice, EDH-mediated relaxations to acetylcholine were markedly reduced and the remaining relaxations were inhibited by L-NNA and indomethacin, indicating the compensatory roles of NO and prostacyclin ( Figure 3A ). Moreover, in mesenteric arteries of eAMPKα 1 −/− α 2 +/+ mice, EDH-mediated relaxations were significantly impaired when compared with controlα 1 f/f α 2 +/+ mice ( Figure 3B ), whereas the same extent of relaxations was noted in both eAMPKα 1 +/+ α 2 −/− and control α 1 +/+ α 2 f/f mice ( Figure 3C ). In eAMPKα 1 −/− α 2 −/− mice, endothelium-independent relaxations to sodium nitroprusside (a NO donor) were rather significantly impaired but showed biphasic responses in mesenteric artery ( Figure IX 
Important Role of eAMPK in Coronary Flow Regulation
Discussion
The novel finding of the present study with eAMPK-KO mice was that α l subunit of eAMPK plays an important role in EDH responses in resistance arteries and blood pressure control in mice. Although NO and prostacyclin play some compensatory roles, the extent of the compensation was not enough to prevent blood pressure elevation. To the best of our knowledge, this is the first study that demonstrates that eAMPK plays an important role in regulating blood pressure and coronary flow responses through EDH mechanisms ( Figure 6 ). 
Endothelial AMPK Mediates EDH
EDH is mediated by multiple mechanisms involving endothelial and vascular smooth muscle cell components, and several candidates have been proposed as a nature of EDHF, including H 2 O 2 . 3, 6, 7, 9, 34 Recently, Prysyazhna et al 15 showed that dimerization of protein kinase G 1α plays an important role in H 2 O 2 -mediated vascular smooth muscle cell relaxation, which finding was subsequently confirmed in the human coronary artery. 35 We have also previously demonstrated that the 3 NOS isoforms in the endothelium are important sources of H 2 O 2 as an EDHF, 3, 9, 10 and endothelial Cu,Zn-SOD plays an important role as an EDHF synthase, 36 and recently summarized in our findings related to these issues. 37 Interestingly, AMPK is the only kinase that can phosphorylate eNOS on ≥1 site, including Ser1177 30 and Ser633 29 as activating sites in the reductase domain and Thr495 as an inhibitory site in the calmodulin-binding domain. 38, 39 Recently, we have demonstrated that eNOS is functionally inhibited under physiological conditions through reduced phosphorylation at Ser1177 and increased phosphorylation at Thr495. 33 In the present study, we were able to demonstrate that endothelial AMPKα 1 substantially mediates EDH in mouse resistance arteries (eg, mesenteric and coronary arteries) but not in the aorta. eNOS is activated in a Ca 2+ -dependent manner, 40 and NO itself acts as an endogenous activator of AMPK in a Ca 2+ -dependent manner, involving CaMKKβ. 41 An increase in endothelial Ca 2+ , crucial step in EDH mechanism, 34, 39 activates Ca 2+ /CaMdependent protein kinase β with resultant AMPK activation. 42 H 2 O 2 could activate endothelial AMPK through Ca 2+ / CaM-dependent protein kinase β pathway within its physiological concentrations, which could be a possible important feedback mediator of AMPK. 43 In the present study, we found that vascular smooth muscle cell hyperpolarization of mesenteric arteries (in the presence of NO and prostacyclin inhibitors) was significantly impaired in eAMPK-KO mice with reduced relaxation responses, indicating that eAMPK is substantially involved in EDH responses. 44 
Mechanisms of eAMPK-Mediated EDH
Although no drug is currently available to improve EDHmediated responses directly, beneficial indirect effects of several drugs on EDH-mediated responses have been reported, including angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers. 5, 45 Our previous study showed that EDH component was not restored by the antihypertensive treatment with hydralazine in eNOS-KO mice. 9 In the present study, we found that hydralazine failed to restore EDH-dependent relaxations in mesenteric arteries of eAMPKα 1 −/− α 2 −/− mice. These results indicate that the impaired EDH-mediated responses in eAMPKα 1 −/− α 2 −/− mice were not the results of elevated blood pressure but were directly related to eAMPK. Nonpharmacological therapeutic strategies, including exercise and supplementation with estrogens, ω3polyunsaturated fatty acids, and polyphenol derivatives have been reported to improve endothelial dysfunction with reduced EDH-mediated responses. 5 Moreover, several pharmacological agents are known to activate AMPK, including glitazones and biguanides, by indirect pathways in whole organism. 24 Metformin, a biguanide derivative, is one of the most commonly used drug for the treatment of type 2 diabetes mellitus. 46 of metformin treatment, its effects on endothelium-dependent responses remain to be examined. It was recently reported that metformin improved vascular dysfunction and increased EDH-mediated relaxations in diabetic rats, 47 and that α 1 -subunit of AMPK is involved in the beneficial effects of exercise and prevention of diabetic vascular dysfunction in mice. 48, 49 In the present study, metformin failed to restore EDH-mediated responses in mesenteric arteries of eAMPKα 1 −/− α 2 −/− mice but enhanced the endotheliumdependent compensatory responses mediated by NO and prostacyclin. 47 The present findings could provide clues to develop new therapeutic strategy for the treatment and the prevention of metabolic cardiovascular diseases with a special reference to AMPK.
Limitations
Several limitations should be mentioned for the present study. First, intracellular signaling pathways linking AMPKα 1 and EDH remain to be fully elucidated. In mouse mesenteric and coronary arteries, the major EDHF is H 2 O 2 derived from eNOS as we have previously demonstrated. 9, 10, 17, 36 Although we have recently demonstrated the involvement of CaMKKβ, caveolin-1, and AMPK in eNOS activation as an EDHF synthase in mice, 33 the intracellular signaling pathway linking AMPKα 1 and EDH remains to be fully elucidated in future studies. Second, in the present study, we examined the roles of endothelial AMPK in EDH only under normal conditions but not under pathological metabolic conditions, such as diabetes mellitus and hyperlipidemia. Third, glucose tolerance and lipid profiles were fairly preserved in eAMPKα 1 −/− α 2 −/− mice. It remains to be examined whether some other unknown compensatory mechanisms are involved to maintain glucose tolerance and lipid profiles in those mice.
Clinical Implications
As discussed above, AMPK serves as an important metabolic regulator. 19 Activation of AMPK in whole body is known to exert beneficial effects in obesity, metabolic syndrome, and diabetes mellitus associated with hypertension. 19 However, the long-term effects of systemic activation of AMPK remains controversial, and tissue-specific role of endothelial AMPK remains to be elucidated. 19, 22 The present study suggests that genetically induced dysfunction of endothelial AMPK causes EDH impairment with resultant hypertension in mice, suggesting the involvement of dysfunction of endothelial AMPK in the pathogenesis of hypertension and impaired coronary flow responses in patients with metabolic disorder.
In conclusions, we were able to demonstrate that α 1 -subunit of eAMPK substantially mediates EDH responses of resistance arteries and thus regulates blood pressure and coronary flow responses in mice in vivo, demonstrating the novel role of eAMPK in cardiovascular homeostasis.
